On August 11, 2026, the clinical trial registry updated the status of a study involving insulin glargine to completed. The trial, titled "This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus," is registered under identifier NCT00418522. It is listed as a Phase 4 study.
Phase 4 trials are conducted after a drug has received regulatory approval and typically monitor its use in broader clinical settings. Insulin glargine itself holds approved regulatory status. The registry entry confirms only that the study has reached completed status as of the listed date.
No results, outcomes, or efficacy data are included in this update. The completion status indicates that the trial has concluded its planned activities, but does not itself convey findings. Readers should not infer any conclusions about inhaled insulin or insulin glargine from the status change alone.
Further details about the trial, including any eventual results, would be expected to appear in the official registry record or subsequent publications. For additional background on insulin glargine, readers can consult the compound overview.